Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
PGEN

Precigen Inc

PGEN

1.18USD+0.01 (+0.85%)Market Closed
Watchlist

Market Summary

USD1.18+0.01
Market Closed
0.85%

PGEN Stock Price

View Fullscreen

PGEN RSI Chart

PGEN Valuation

Market Cap

302.6M

Price/Earnings (Trailing)

-3.56

Price/Sales (Trailing)

13.69

EV/EBITDA

-3.8

Price/Free Cashflow

-4.51

PGEN Price/Sales (Trailing)

PGEN Profitability

EBT Margin

-385.21%

Return on Equity

-57.57%

Return on Assets

-44.59%

Free Cashflow Yield

-22.18%

PGEN Fundamentals

PGEN Revenue

Revenue (TTM)

22.1M

Revenue Y/Y

-39.3%

Revenue Q/Q

-4.54%

PGEN Earnings

Earnings (TTM)

-85.0M

Earnings Y/Y

-122.65%

Earnings Q/Q

2.58%

Price Action

Last 7 days

-0.8%

Last 30 days

-6.3%

Last 90 days

-27.2%

Trailing 12 Months

-25.8%

How does PGEN drawdown profile look like?

PGEN Financial Health

Current Ratio

2.83

PGEN Investor Care

Shares Dilution (1Y)

23.18%

Diluted EPS (TTM)

-0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202323.2M22.1M00
202216.3M15.4M28.8M26.9M
202197.9M71.2M51.0M35.3M
202098.0M95.6M100.8M103.2M
2019134.1M121.7M107.5M90.7M
2018217.1M208.0M194.4M151.2M
2017201.2M203.2M200.2M231.2M
2016183.2M190.8M186.4M190.9M
201597.9M131.0M163.2M173.6M
201427.7M32.8M48.0M71.9M
201316.1M20.1M23.2M23.8M
20129.5M10.9M12.3M13.8M
20110008.0M

Latest Insider Trading transactions for PGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 22, 2023
mitchell dean j
bought
35,250
1.41
25,000
-
Aug 25, 2023
sabzevari helen
sold
-117,763
1.53
-76,969
president and ceo
Aug 24, 2023
shah rutul r
sold
-8,836
1.64
-5,388
chief operating officer
Aug 24, 2023
lehr donald p.
sold
-17,953
1.64
-10,947
chief legal officer
Aug 24, 2023
perez jeffrey thomas
sold
-14,581
1.64
-8,891
svp, ip affairs
Aug 24, 2023
thomasian harry jr.
sold
-14,833
1.64
-9,045
chief financial officer
Aug 23, 2023
shah rutul r
acquired
-
-
15,480
chief operating officer
Aug 23, 2023
thomasian harry jr.
acquired
-
-
17,934
chief financial officer
Aug 23, 2023
sabzevari helen
acquired
-
-
141,587
president and ceo
Aug 23, 2023
lehr donald p.
acquired
-
-
21,710
chief legal officer

1–10 of 50

Which funds bought or sold PGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-92.69
-46,626
4,628
-%
Nov 24, 2023
DEUTSCHE BANK AG\
unchanged
-
15,457
81,292
-%
Nov 22, 2023
Graham Capital Management, L.P.
reduced
-46.21
-13,950
27,596
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
reduced
-49.22
-581,094
976,667
0.01%
Nov 16, 2023
Creative Planning
added
0.94
64,460
326,092
-%
Nov 15, 2023
Opaleye Management Inc.
new
-
1,318,470
1,318,470
0.43%
Nov 15, 2023
Tudor Investment Corp Et Al
unchanged
-
19,295
101,479
-%
Nov 15, 2023
JANE STREET GROUP, LLC
new
-
46,816
46,816
-%
Nov 15, 2023
GSA CAPITAL PARTNERS LLP
new
-
475,000
475,000
0.04%
Nov 15, 2023
MORGAN STANLEY
added
3.41
299,464
1,380,880
-%

1–10 of 46

Latest Funds Activity

Are funds buying PGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PGEN
No. of Funds

Schedule 13G FIlings of Precigen Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 31, 2023
kirk randal j
38.3%
96,360,443
SC 13D/A
Jan 27, 2023
ares trading s.a.
9.92%
20,647,152
SC 13G/A
Jan 24, 2022
ares trading s.a.
9.99%
20,647,152
SC 13G/A
Feb 16, 2021
miller value partners, llc
3.85%
7,134,094
SC 13G/A
Jan 08, 2021
ares trading s.a.
14.8%
27,398,519
SC 13G/A
Dec 21, 2020
kirk randal j
43.6%
81,822,163
SC 13D/A
Aug 13, 2020
kirk randal j
48.7%
8.4e+07
SC 13D/A
Feb 14, 2020
miller value partners, llc
5.17%
8,416,710
SC 13G
Feb 04, 2020
kirk randal j
48.2%
81,523,936
SC 13D/A
Jan 22, 2020
ares trading s.a.
14.9%
24,852,348
SC 13G/A

Recent SEC filings of Precigen Inc

View All Filings
Date Filed Form Type Document
Nov 09, 2023
8-K
Current Report
Nov 09, 2023
10-Q
Quarterly Report
Sep 25, 2023
4
Insider Trading

Peers (Alternatives to Precigen Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.5B
-
6.13% 411799.31%
-3.7K
218.4K
- -102.45%
30.6B
10.7B
12.59% -56.51%
-8.83
2.87
-53.67% -129.46%
21.3B
1.7B
0.38% -28.56%
-41.84
12.38
79.37% 56.87%
17.5B
2.3B
8.71% -10.95%
119.09
7.58
15.05% 75.21%
12.3B
3.6B
1.18% -34.97%
28.84
3.4
8.35% -51.49%
MID-CAP
7.4B
272.9M
33.62% 24.68%
-12.26
27.23
141.38% 4.43%
5.7B
-
10.65% 240.88%
-9.69
48.33
54.84% -12.96%
3.4B
631.9M
-9.53% 43.40%
-23.12
5.44
23.54% 31.53%
3.3B
223.4M
14.00% -9.85%
-16.45
14.86
- -26.24%
2.6B
240.7M
-11.63% -24.14%
-12.52
10.67
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
12.92% -15.71%
24.33
4.33
81.69% -7.29%
661.3M
1.0B
-18.09% -67.84%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.35%
-0.61
15.6
-44.11% 50.48%
37.6M
-
385.71% 119.35%
-0.58
-
- -29.23%
23.7M
-
40.31% 4064.72%
-0.5
-
- -13.74%

Precigen Inc News

Latest updates
Stocks Register09 Dec 202308:05 pm89 minutes ago
InvestorPlace22 Nov 202308:00 am17 days ago
InvestorsObserver10 Nov 202308:00 am29 days ago
PR Newswire09 Nov 202308:00 am30 days ago
Best Stocks09 Nov 202307:06 am30 days ago
PR Newswire07 Nov 202308:00 am32 days ago
Simply Wall St04 Nov 202307:00 am35 days ago
Yahoo Finance05 Sep 202307:00 am3 months ago
Seeking Alpha28 Aug 202307:00 am3 months ago
Seeking Alpha23 Aug 202307:00 am3 months ago
Simply Wall St17 Aug 202307:00 am3 months ago
Penny Stocks17 Aug 202307:00 am3 months ago
PR Newswire14 Aug 202307:00 am3 months ago
PR Newswire14 Aug 202307:00 am3 months ago

Financials for Precigen Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-4.5%1,767,0001,851,0001,763,00016,722,0002,911,0005,513,0003,684,0003,333,0003,815,00024,511,00019,333,00023,583,00030,424,00029,838,00017,002,00018,299,00032,836,00022,585,00033,789,00032,448,00045,275,000
Operating Expenses----------------71,660,00073,395,00082,038,000380,002,50098,919,00095,010,000
  S&GA Expenses----------------24,741,00021,483,00033,594,00024,935,00038,708,00034,427,000
  R&D Expenses----------------31,480,00034,518,00033,062,000280,449,50044,885,00042,049,000
EBITDA Margin2.1%-2.68-2.74-2.25--1.05-1.09-0.73-1.53-1.45-0.72-0.77-1.10-1.35-1.12-------
Interest Expenses-74.9%232,000924,000348,0004,619,00033,0003,535,00039,0003,538,00039,0003,539,00047,0003,543,00044,0003,568,000-2,551,0004,471,0004,358,00077,000-372,0003,999,000142,000
Income Taxes-18.2%-65,000-55,000-90,500-50,000-89,000-58,000-164,000--4,000-130,0008,000-40,000-451,500-512,000-525,00030,0004,110,000-14,322,000-1,127,000
Earnings Before Taxes10.6%-20,384,000-22,789,000-22,168,000-7,694,000-26,148,000-23,956,000-29,188,500-26,380,000-30,999,000-21,896,000-40,303,000-27,586,000-15,829,000-20,806,000-36,980,000-49,057,000-32,314,000-52,913,000-203,393,000-73,068,000-67,956,000
EBT Margin2.5%-3.30-3.39-2.97--1.24-1.29-0.93-1.77-1.69-0.96-1.01-1.28-1.55-1.36-------
Net Income10.6%-20,319,000-22,734,000-22,176,00087,379,000-17,635,000-19,251,000-25,034,000-29,764,000-20,050,000-17,318,000-41,661,000-29,508,000-43,354,000-55,998,000-169,215,000-53,634,000-38,766,000-60,709,000-340,465,000-57,324,000-65,382,000
Net Income Margin-6.2%1.001.071.05--1.14-1.15-0.89-1.57-1.52-1.35-1.65-2.96-3.21-3.00-------
Free Cashflow14.4%-15,869,000-18,542,000-15,449,000-25,387,000-8,771,000-20,362,000-17,362,000-19,288,000-8,970,000-17,398,000-17,938,000-20,028,000-15,687,000-30,895,000-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-8.1%191208242216259321336360377403407315336362405456605655710716980
  Current Assets-12.0%93.00106138118163165155157153157144149151173189235157183232285310
    Cash Equivalents-37.5%10.0017.0010.005.009.0050.0041.0043.0042.0037.0028.0052.0028.0047.0038.0068.0045.0059.0010711090.00
  Net PPE8.2%7.007.007.007.008.008.0034.009.0033.0033.0034.0035.0045.0047.0060.0044.0012312013687.00123
  Goodwill-0.2%37.0037.0037.0037.0037.0037.0054.0038.0054.0054.0054.0054.0054.0054.0064.0054.0014815015194.00151
Liabilities4.1%43.0041.0057.0090.00117266262253246243232247278312317384376376375337425
  Current Liabilities6.8%33.0031.0047.0079.0010530.0026.0035.0029.0029.0025.0042.0031.0064.0071.0012382.0052.0059.0062.0092.00
  Short Term Borrowings---14.0043.00-----------------
    LT Debt, Current----43.0082.00-0.000.000.000.000.000.000.0032.0032.0032.0031.000.001.000.001.00
    LT Debt, Non Current------199201180180177174172194191189186184212214211183
Shareholder's Equity-11.1%14816618412614356.0074.0010713115917567.0059.0050.0087.0072.00228279335379555
  Retained Earnings-1.0%-1,931-1,911-1,891-1,868-1,846-1,933-1,916-1,915-1,890-1,860-1,840-1,823-1,781-1,752-1,708-1,652-1,483-1,430-1,391-1,330-990
  Additional Paid-In Capital0.1%2,0832,0802,0781,9981,9961,9941,9922,0232,0202,0172,0141,8871,8391,8021,7971,7521,7451,7371,7331,7221,552
Shares Outstanding0.4%256255255208208200200207199199193188166164160163154153153130129
Minority Interest-------------------22.0016.0016.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-7.9%-17,008,000-15,768,000-18,388,000-15,396,000-23,813,000-7,053,000-18,783,000-14,589,000-17,022,000-7,776,000-16,384,000-16,469,000-19,004,000-13,805,000-27,743,000-32,142,000-27,148,000-33,403,000-43,234,000-37,362,000-28,820,000
  Share Based Compensation5.3%2,306,0002,189,0003,131,0002,210,0002,125,0002,309,0003,562,0002,442,0002,490,0003,557,0005,415,0004,497,0004,600,0004,897,0004,372,0004,412,0005,423,00061,0009,054,0007,956,0008,132,000
Cashflow From Investing-55.2%10,525,00023,503,000-50,408,00011,421,000181,855,00016,573,00016,568,00015,929,00022,013,00016,620,000-129,102,00040,184,000181,00023,967,000-36,553,00054,509,00013,777,000-15,027,00033,592,00030,741,000-161,034,000
Cashflow From Financing100.0%--14,585,00044,174,000-39,282,000-115,734,000-113,000-163,000-110,000234,00023,000121,040,000-72,000-114,000-1,260,00034,151,0001,199,00045,000-33,0006,927,00027,249,000193,600,000

PGEN Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses    
Impairment of goodwill  $ 0$ 482
Impairment of other noncurrent assets  0638
Other income (Expense), Net    
Equity in net income (loss) of affiliates  0861
Loss from continuing operations before income taxes$ (19,801)$ (7,694)(62,974)(57,798)
Income tax benefit650126197
Income from discontinued operations, net of income taxes095,0230108,094
Net (loss) income$ (19,795)$ 87,379$ (62,848)$ 50,493
Net (loss) income per share    
Net loss from continuing operations per share, basic (in dollars per share)$ (0.08)$ (0.04)$ (0.26)$ (0.29)
Net loss from continuing operating per share, diluted (in dollars per share)(0.08)(0.04)(0.26)(0.29)
Net income from discontinued operations per share, diluted (in dollars per share)00.4800.54
Net income from discontinued operations per share, basic (in dollars per share)00.4800.54
Net (loss) income per share, basic (in dollars per share)(0.08)0.44(0.26)0.25
Net (loss) income per share, diluted (in dollars per share)$ (0.08)$ 0.44$ (0.26)$ 0.25
Weighted average shares outstanding, basic (in shares)248,520,724200,670,590243,075,262200,256,046
Weighted average shares outstanding, diluted (in shares)248,520,724200,670,590243,075,262200,256,046
Continuing Operations    
Revenues    
Total revenues$ 1,379$ 16,722$ 4,997$ 25,146
Operating Expenses    
Research and development11,58312,62235,62036,377
Selling, general and administrative9,19610,13730,15036,496
Impairment of goodwill000482
Impairment of other noncurrent assets000638
Total operating expenses22,31624,33670,53179,075
Operating loss(20,937)(7,614)(65,534)(53,929)
Other income (Expense), Net    
Interest expense(1)(2,036)(461)(6,137)
Interest income856562,316131
Other income, net2811,0387051,276
Total other income (expense), net1,136(942)2,560(4,730)
Equity in net income (loss) of affiliates08620861
Loss from continuing operations before income taxes(19,801)(7,694)(62,974)(57,798)
Income tax benefit650126197
Loss from continuing operations(19,795)(7,644)(62,848)(57,601)
Continuing Operations | Collaboration and licensing revenues    
Revenues    
Total revenues014,561014,561
Continuing Operations | Product revenues    
Revenues    
Total revenues823427301,455
Continuing Operations | Service revenues    
Revenues    
Total revenues1,2961,7504,2618,896
Operating Expenses    
Cost of products and services1,5371,5774,7615,082
Continuing Operations | Other revenues    
Revenues    
Total revenues$ 1$ 69$ 6$ 234

PGEN Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 10,076,000$ 4,858,000
Restricted cash043,339,000
Short-term investments63,679,00051,092,000
Receivables  
Trade, less allowance for credit losses of $184 as of both September 30, 2023 and December 31, 2022988,000978,000
Other13,117,00012,826,000
Prepaid expenses and other5,128,0005,066,000
Total current assets92,988,000118,159,000
Long-term investments5,271,0000
Property, plant and equipment, net7,115,0007,329,000
Intangible assets, net40,426,00044,455,000
Goodwill36,894,00036,923,000
Right-of-use assets7,197,0008,086,000
Other assets797,0001,025,000
Total assets190,688,000215,977,000
Current liabilities  
Accounts payable2,351,0004,068,000
Accrued compensation and benefits6,621,0006,377,000
Other accrued liabilities4,119,0004,997,000
Settlement and indemnification accruals18,075,00018,750,000
Deferred revenue509,00025,000
Current portion of long-term debt043,219,000
Current portion of lease liabilities1,200,0001,209,000
Total current liabilities32,875,00078,645,000
Deferred revenue, net of current portion1,818,0001,818,000
Lease liabilities, net of current portion6,192,0006,992,000
Deferred tax liabilities2,125,0002,263,000
Total liabilities43,010,00089,718,000
Commitments and contingencies (Note 14)
Shareholders' equity  
Common stock, no par value, 400,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 256,398,527 shares and 208,150,021 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively00
Additional paid-in capital2,082,654,0001,998,314,000
Accumulated deficit(1,931,415,000)(1,868,567,000)
Accumulated other comprehensive loss(3,561,000)(3,488,000)
Total shareholders' equity147,678,000126,259,000
Total liabilities and shareholders' equity$ 190,688,000$ 215,977,000
PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
 CEO
 WEBSITEprecigen.com
 EMPLOYEES209

Precigen Inc Frequently Asked Questions


What is the ticker symbol for Precigen Inc? What does PGEN stand for in stocks?

PGEN is the stock ticker symbol of Precigen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precigen Inc (PGEN)?

As of Fri Dec 08 2023, market cap of Precigen Inc is 302.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PGEN stock?

You can check PGEN's fair value in chart. The fair value of Precigen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Precigen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Precigen Inc a good stock to buy?

The fair value guage provides a quick view whether PGEN is over valued or under valued. Whether Precigen Inc is cheap or expensive depends on the assumptions which impact Precigen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PGEN.

What is Precigen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, PGEN's PE ratio (Price to Earnings) is -3.56 and Price to Sales (PS) ratio is 13.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Precigen Inc's stock?

In the past 10 years, Precigen Inc has provided -0.244 (multiply by 100 for percentage) rate of return.